Table 1 Enriched pathways in Ramos640 vs Ramos cells based on an antibody microarray for profiling phosphorylation
From: Midostaurin potentiates rituximab antitumor activity in Burkitt’s lymphoma by inducing apoptosis
KEGG pathway | P value | Fold enrichment | Count | Genes |
|---|---|---|---|---|
hsa04151: PI3K-Akt signaling pathway | 2.47E−15 | 18.60 | 13 | CDKN1A, PTK2, CDKN1B, BCL2, CREB1, TP53, BAD, BCL2L1, ITGB3, PTEN, MYC, CHUK, AKT2 |
hsa05200: Pathways in cancer | 1.24E−12 | 15.07 | 12 | CDKN1A, PTK2, CDKN1B, JUN, BCL2, TP53, BAD, BCL2L1, PTEN, MYC, CHUK, AKT2 |
hsa04012: ErbB signaling pathway | 5.35E−09 | 39.71 | 7 | CDKN1A, PTK2, CDKN1B, JUN, BAD, MYC, AKT2 |
hsa05169: Epstein-Barr virus infection | 1.59E−08 | 20.78 | 8 | CDKN1A, CDKN1B, JUN, BCL2, TP53, MYC, CHUK, AKT2 |
hsa04210: Apoptosis | 6.01E−08 | 47.76 | 6 | BCL2, TP53, BAD, BCL2L1, CHUK, AKT2 |
hsa04510: Focal adhesion | 9.41E−07 | 16.77 | 7 | PTK2, JUN, BCL2, BAD, ITGB3, PTEN, AKT2 |
hsa05206: microRNAs in cancer | 6.28E−06 | 12.12 | 7 | CDKN1A, CDKN1B, BCL2, TP53, ITGB3, PTEN, MYC |
hsa05202: Transcriptional misregulation in cancer | 8.80E−06 | 17.63 | 6 | CDKN1A, PTK2, CDKN1B, TP53, BCL2L1, MYC |
hsa05205: Proteoglycans in cancer | 2.06E−05 | 14.81 | 6 | CDKN1A, PTK2, TP53, ITGB3, MYC, AKT2 |
hsa05203: Viral carcinogenesis | 2.32E−05 | 14.45 | 6 | CDKN1A, CDKN1B, JUN, CREB1, TP53, BAD |
